Skip to main content

enGene Therapeutics Inc. insider trading

ENGNNASDAQ
$1.94-0.04 (-2.02%)as of Oct 2, 2026

“Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” — Peter Lynch

Insider Trading vs Stock Price

Insider Trading vs Stock Price data

Showing the 1Y range: Oct 2, 2025 to Oct 2, 2026. Price (-76.2%). 0 insider transactions plotted in this window as 0 markers; nearby trades of the same kind are grouped.

Transactions plotted on the price chart
DateCategoryPersonRoleActionAmountChange in holding
Open market purchase
Open market sell
Marker size reflects transaction size.

Net dollar flow · Buy / Sell balance

Premium
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Unlock quarterly net flow

Key players

  • PAPhilip Astley-SparkeDirector0.0298%of company
  • MRMatthew Ross BoydChief Regulatory Officer0.0112%of company
  • KPKathleen P. RichtonSVP, Finance and Treasurer0.0103%of company
  • WGWilliam GrossmanInterim Chief Medical Officer0.0076%of company
  • FGForbion Growth Opportunities Fund I Cooperatief U.A.10% OwnerNot reportedof company
  • FGForbion Growth Management B.V.10% OwnerNot reportedof company

AI Activity Analysis

Premium
Coming soonAI reads of insider activity will appear here for Premium accounts.

Insider activity

Fromto
CompanyInsider / roleActionΔOwnAvg priceAmount
ENGNWilliam GrossmanInterim Chief Medical OfficerOpen market purchase$10.1KNot reported$1.97$10.1KSep 22, 2026Sep 24, 2026
End of history · 1 transactions
SpoorBase

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.